Clinical trials evaluating BET inhibitors with results in patients with... | Download Scientific Diagram
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
Table 1 from Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence | Semantic Scholar
Summary of BET inhibitor clinical trials (open Dec. 2017). | Download Table
Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs - RSC Advances (RSC Publishing) DOI:10.1039/D0RA07971E
Targeting MYC dependence in cancer by inhibiting BET bromodomains | PNAS
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer - eBioMedicine
Achieving clinical success with BET inhibitors as anti-cancer agents | British Journal of Cancer
BET inhibitors in the treatment of hematologic malignancies: current i | OTT
Two pathways, one destination: promising drug combination to treat ovarian cancer
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study - The Lancet Haematology
Frontiers | Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials | Pharmacology
Ongoing clinical trials evaluating BET inhibitors in hematological cancers. | Download Scientific Diagram
Drug Toxicities With BET Inhibitors in Clinical Trials a | Download Table
BET bromodomain inhibitor | Epigenetic Reader Domain Inhibitor | MedChemExpress
Differentiation therapy of myeloid leukemia: four decades of development | Haematologica
Frontiers | Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials | Pharmacology
Sierra Signs Exclusive Deal with AstraZeneca for Potent BRD4 BET Inhibitor | BioSpace
BeT inhibitors in ongoing early-phase clinical trials for hematologic... | Download Table
Bromodomain Inhibitor Design For Epigenetic Cancer Therapies and Chemical Probes | Pomerantz Laboratory
Cancers | Free Full-Text | Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications | HTML
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer - ScienceDirect
Cancers | Free Full-Text | Role of BET Inhibitors in Triple Negative Breast Cancers | HTML
